5GH.F GUARDANT HEALTH CL. A

Healthcare Biotechnology Frankfurt Exchange
141.42 EUR
Close of Nov 11, 2026
66.48 166.44
Market cap
EUR 19.1B
P/E
-
P/B
53.66x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 5GH.F undervalued?

Graham number

The Graham number of GUARDANT HEALTH CL. A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GUARDANT HEALTH CL. A fundamental analysis

No fundamental analysis for GUARDANT HEALTH CL. A yet.

GUARDANT HEALTH CL. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GUARDANT HEALTH CL. A

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a …

Full company profile